CD4 and autoimmune disease: The unique and cell type-specific role of cathepsin S thus represents an opportunity for potential therapeutic intervention in autoimmune diseases with significant pathogenic involvement of CD4+ T cells, and therefore cathepsin S has become an appealing target for drug development (14–16).